CM
AERI

Crestline Management’s Aerie Pharmaceuticals AERI Stock Holding History

Crestline Management’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-18,024
Closed -$947K – 184
2017
Q2 		$947K Buy
+18,024
New +$839K 0.13% 90

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Crestline Management's AERI Position: Q3 2017 in Review

Crestline Management sold out of Aerie Pharmaceuticals (AERI) in Q3 2017, closing a stake of 18,024 shares — an estimated $947K sold.

Crestline Management first reported a position in AERI in Q2 2017 and held it in 1 quarter. The position peaked at $947K in Q2 2017. 182 funds tracked by Wall St. Rank hold AERI as of Q3 2017.

  • Crestline Management reported no remaining Aerie Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Crestline Management sold 18,024 Aerie Pharmaceuticals shares in Q3 2017, an estimated $947K.
  • Crestline Management first reported a position in Aerie Pharmaceuticals in Q2 2017 and held it in 1 quarter.
  • Crestline Management's Aerie Pharmaceuticals position peaked at $947K in Q2 2017.
  • 182 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2017.

Based on Crestline Management's 13F filing for Q3 2017, filed 14 Nov 2017.